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Chronic kidney disease (CKD) has become a heavy burden globally with rising 
prevalence. Irrespective of the underlying etiology, renal fibrosis occurs in virtually every 
type of CKD. The transient receptor potential cation channel subfamily C member 6 
(TRPC6) is widely expressed in renal tissues and has been implicated in renal fibrosis. 
The aims of this study were (i) to examine whether deletion of TRPC6 impacts on renal 
fibrosis and inflammatory cell infiltration in an early CKD model of unilateral ureter 
obstruction (UUO) in mice and (ii) whether TRPC6-deficiency as well as UUO affect the 
regulation of TRPC channel expression in murine kidneys. 
 
Materials and Methods: 
 
UUO- and sham-surgeries were performed in 9-12 weeks old male Trpc6-/- mice, wild-
type (WT) controls and New Zealand obese (NZO) mice. Seven days after surgery, the 
mice were sacrificed and the kidneys were harvested for further analyses. Renal fibrosis 
and inflammatory cell infiltration were evaluated by histological and immunohistochemical 
staining. The mRNA expression of TRPC channels and markers of fibrosis and 





Histological and immunohistochemical analyses revealed less fibrosis and inflammatory 
cell infiltration in UUO kidneys of Trpc6-/- mice compared to UUO kidneys of WT mice. Of 
note, genomic deletion of TRPC6 also affected the expression of pro-fibrotic genes in 
UUO Trpc6-/- kidneys compared to UUO WT kidneys while the expression of pro-
inflammatory genes remained unchanged. Sham and UUO-operated kidneys of WT, 
Trpc6-/- and NZO mice were examined to compare the gene expression of TRPC 
members. It emerged that UUO caused marked up-regulation of Trpc6 mRNA in kidneys 
of WT and NZO mice. These studies also revealed that UUO caused profound changes 
ix 
 
in renal expression of multiple other TRPC genes in the presence and absence of TRPC6, 




TRPC6 contributes to renal fibrosis and immune cell infiltration in the UUO mouse model. 
Therefore, inhibition of TRPC6 emerges as a promising novel therapeutic strategy for 
treatment of chronic kidney failure in chronic obstructive nephropathy, including in mice 
carrying susceptibility genes for obesity, diabetes and hypertension. However, 
confounding genomic and non-genomic effects of other TRPC channels should be taken 
into consideration to fully comprehend the renoprotective potential of targeting TRPC6 











Chronische Nierenerkrankung (CKD) ist eine ernst zu nehmende Erkrankung mit weltweit 
steigender Inzidenz und Prävalenz, die eine Belastung der öffentlichen 
Gesundheitssysteme geworden ist. Nierenfibrose tritt unabhängig von der zugrunde 
liegenden Ätiologie bei jeder Art von CKD auf. Der TRPC6-Kanal (für „transient receptor 
potential cation channel subfamily C member 6“) wird in der Niere umfassend exprimiert 
und ist an der Pathogenese der Nierenfibrose beteiligt. Die Ziele dieser Arbeit waren (i) 
zu untersuchen, ob das Ausschalten von TRPC6 auf die Nierenfibrose und die 
Entzündungszellinfiltration in frühen Stadien der CKD im Mausmodell der unilateralen 
Ureterobstruktion (UUO) wirkt; und (ii) ob TRPC6-Mangel sowie UUO die Regulation der 
TRPC-Kanal-Expression in Mäusenieren beeinflussen. 
 
Materialien und Methoden: 
 
UUO- und Schein-Operationen wurden in 9-12 Wochen alten männlichen Trpc6-/- Mäusen, 
Wildtyp (WT) -Kontrollen und NZO (New Zealand obese) Mäusen durchgeführt. 7 Tage 
nach der Operation wurden die Mäuse getötet und die Nieren für weitere Analysen 
geerntet. Nierenfibrose und entzündliche Zellinfiltration wurden durch histologische und 
immunhistochemische Färbungen bewertet. Die mRNA-Expression von TRPC-Kanälen 





Histologische und immunhistochemische Analysen zeigten eine geringere Fibrose und 
entzündliche Zellinfiltration in UUO-Nieren von Trpc6-/- Mäusen im Vergleich zu UUO-
Nieren von WT-Mäusen. Bemerkenswerterweise beeinflusste das genomische 
Ausschalten von TRPC6 auch die Expression der pro-fibrotischen Gene in UUO-Trpc6-/-
-Nieren im Vergleich zu UUO-WT-Nieren, während die Expression der pro-
inflammatorischen Gene unverändert blieb. Schein- und UUO-operierte Nieren von WT-, 
xi 
 
Trpc6-/-- und NZO-Mäusen wurden auch untersucht, um die Genexpression von TRPC-
Mitgliedern zu vergleichen. Es zeigte sich, dass UUO in den Nieren von WT- und NZO-
Mäusen eine deutliche Hochregulierung der Trpc6-mRNA verursachte. Die Studie hat 
auch herausgestellt, dass UUO in Anwesenheit oder Abwesenheit von TRPC6-
Veränderungen der renalen Expression mehrerer anderen TRPC-Gene verursacht, was 




TRPC6 trägt im UUO-Mausmodell, einschließlich bei Mäusen, die die 
Empfindlichkeitsgene für Fettleibigkeit, Diabetes und Bluthochdruck tragen, zur 
Nierenfibrose und zur Infiltration von Immunzellen bei. Daher ist die Hemmung von 
TRPC6 eine vielversprechende neue Therapiestrategie für die Behandlung von 
chronischem Nierenversagen bei chronisch obstruktiver Nephropathie. Allerdings sollten 
umfassende genomische und nicht-genomische Wirkungen anderer TRPC-Kanäle 
berücksichtigt werden, um das renoprotektive Potenzial der therapeutischen Behandlung 








1.1    Facts about chronic kidney disease 
 
1.1.1    Epidemiology 
 
Chronic kidney disease (CKD) is an irreversible change in kidney structure and function 
caused by a variety of causes. It can last for months or years, and eventually progresses 
to end-stage renal disease (ESRD). About 10%-15% of the population worldwide is 
affected by CKD[1]. The Global Burden of Disease (GBD) study estimated that 1.2 million 
people died from kidney failure in 2015, an increase of 31.7% since 2005[2]. The 
prevalence of CKD is rising worldwide. CKD has become a heavy burden on public health 
resources (Figure 1.1)[3].  
 
 
Figure 1.1: Burden of kidney disease globally. (A) Proportion of total mortality attributed to kidney 
disease. (B) Prevalence of chronic kidney disease. Reprinted from The Lancet, Vol. 389, Webster AC, et 





1.1.2    Etiology and pathophysiology 
 
The causes of CKD include diabetic kidney disease, hypertension, vascular disease, 
glomerular disease (primary or secondary), tubulointerstitial disease, urinary tract 
obstruction or dysfunction, etc. The leading causes of CKD in high-income, middle-
income countries and some low-income countries are diabetes and hypertension [3]. 
 
Renal fibrosis is the inevitable consequence of an excessive accumulation of extracellular 
matrix that occurs in virtually every type of CKD irrespective of the underlying etiology [4]. 
Renal fibrosis is the principal process underlying the progression of CKD to ESRD. It is 
characterized by glomerulosclerosis, tubular atrophy, and deposition of excess matrix in 
the interstitial space surrounding tubules and peritubular capillaries, coupled with the 
appearance of interstitial fibroblasts[3; 5]. The initiation and progression of renal fibrosis 
appear to involve a complex, so far incompletely characterized, interaction between 
injured tubules, pericytes, fibroblasts, endothelial cells and inflammatory cells [5; 6]. 
 
Nephron loss is one of the mechanisms of CKD. By activation of the renin-angiotensin 
system (RAS), transforming growth factor-α (TGFα) and epidermal growth factor receptor 
(EGFR) as compensatory mechanisms, nephron loss causes compensatory hypertrophy 
of residual nephrons to maintain the glomerular filtration rate (GFR)[7]. Podocytes also 
need to undergo hypertrophy to maintain a filtration barrier along the enlarged filtering 
surface. However, beyond a threshold, the dysfunctional barrier manifests mild 
proteinuria[7]. In the later stages of CKD, proteinuria and other potential factors inhibit the 
potential of parietal epithelial cells (PECs) to promote podocyte formation, which in 
contrast promotes scar formation in the form of focal segmental glomerulosclerosis 
(FSGS) (Figure 1.2A)[7]. Glomerular hyperfiltration and proteinuria cause an increase in 
reabsorption of proximal tubules. Albuminuria, complement and immune cells promote 
the release of proinflammatory mediators in tubular cells, develop interstitial inflammatory 
response, further FSGS to global glomerulosclerosis, and promote tubular atrophy and 
interstitial fibrosis. Scar formation is accompanied by vascular reduction and ischemia[7]. 
Therefore, the residual nephrons need to increase in size to adapt to the high filtration 








1.1.3    Therapy 
 
There is no cure for CKD, but it is often treatable. The aim of the treatment is to slow or 
halt the progression of CKD and to prevent serious complications.  
 
In the early stages of CKD, a proper diet and medications are the main treatments.  It is 
important to prevent renal damage and avoid acute kidney injury (AKI) in residual CKD 
Figure 1.2: Mechanisms of CKD. (A) Injury, hyperfiltration and hypertrophy of the nephron. (B) 
Interstitial fibrosis. Adapted by permission from Springer Nature: Springer Nature, Nature Reviews 




nephrons. This includes avoiding nephrotoxic drugs (such as high-dose contrast agents, 
non-steroidal anti-inflammatory drugs (NSAIDs), antibiotics, proton pump inhibitors (PPI), 
other endemic or occupational toxins), and eliminating hypovolemia and urinary tract 
obstruction. Reducing dietary salt intake, and controlling blood pressure, blood glucose 
and blood lipids can further reduce proteinuria and delay CKD progression[7]. 
Angiotensin-converting enzyme inhibitors (ACEI) and angiotensin II receptor blockers 
(ARB) are considered the primary medical therapies for delaying the progression to ESRD. 
Randomized clinical trials have shown that these medications can slow the progression 
of CKD in individuals with proteinuric (diabetic and nondiabetic) kidney disease[8]. 
 
Most people reaching ESRD are treated with renal replacement therapies (RRT), either 
dialysis (hemodialysis, peritoneal dialysis) or kidney transplantation. A number of 
secondary complications associated with CKD and ESRD need to be managed. The most 
relevant complication for all-cause mortality is cardiovascular disease (CVD)[9]. CVD is 
also associated with endocrine disorders (such as lack of erythropoietin, vitamin D3 or 
parathyroid hormone (PTH)) which cause anemia, secondary hyperparathyroidism and 
mineral and bone disorder (MBD). Ultimately, a variety of factors lead to myocardial 
fibrosis[10; 11; 12]. 
 
In summary, treatment of patients with CKD needs to be considered as follows: controlling 
further nephron damage, correcting hyperfiltration of individual nephrons, controlling 
CKD-related complications, and preparing for RRT. The core principle of these treatments 
is "the sooner, the better" in order to slow the progression to ESRD and to optimize kidney 
outcomes[7]. Accordingly, considerable efforts are being made to identify novel drug 




1.2    TRPC in the TRP-superfamily 
 
Transient receptor potential (TRP) channels are a non-selective cation channel 
superfamily with 28 members which are located on the cell membrane based on the 
structural homology and which show all variations in their Ca2+ permeability[13]. The 




melanogaster that responds to a light stimulus with a transient rather than a plateau-
shaped signal[14; 15]. They are widely expressed in a variety of biological cells and are 
involved in many physiological processes such as sensory signaling, osmotic pressure 
regulation, cardiovascular circulation, gastrointestinal motility, airway 
hyperresponsiveness, anal emptying and cell differentiation processes. The TRP 
superfamily can be split into several subfamilies: TRPA (ankyrin), TRPC (canonical), 
TRPM (melastatin), TRPML (mucolipin), TRPN (no mechanoreceptor potential), TRPP 
(polycystin) and TRPV (vanilloid) [16], and in each subfamily there are many subtypes. 




All members of TRPs have an intracellular N- and C-terminus, as well as six 
transmembrane domains (TDs), of which TD 5 and 6 are necessary for the ion channels’ 
pore formation. They show high functional variations in their selectivity for cation 
permeability (Figure 1.4)[17; 18]. All TRPCs and some other TRP proteins contain a 25-
amino-acid domain with a C-terminus invariant sequence EWKFAR, the so-called TRP 
Figure 1.3: Phylogenetic tree of the TRP superfamily. Reprinted from Cell Calcium, Vol. 38, 
Pedersen SF, et al., TRP channels: An overview, 233-252, Copyright (2005), with permission from 




box. Together, TRPC, TRPV, and TRPA display characteristic ankyrin repeats contained 
in the N-terminus[13]. Differences of sequence can be found in the N- and C-terminus as 
well as in the loops connecting the transmembrane domains. In the region of the channel 




The TRPC subfamily is one of the main members of the TRP families. Although TRPC 
channels were the first TRP channels to be cloned and characterized in mammals, their 
physiological role is still not fully clear. All members of the TRPC family have similar 
structures. There are four ankyrin domains at the N-terminus followed by a so-called 
"coiled-coil" region (Figures 1.4 and 1.5). The subsequent transmembrane region is 
followed by a highly conserved TRP domain at the C-terminus. This region is followed by 
calmodulin and the IP3 receptor binding region (CIRB), which binds to phosphoinositide 
(Figure 1.5). Of all the TRP channels, the TRPC channels are most similar to the 
Drosophila TRP channels and are therefore referred to as "classical" or "canonical" as 
indicated by the letter "C" in their name [20; 21]. TRPCs are Ca2+-permeable nonselective 
cation channels and include seven subtypes (TRPC1-7). Based on the similarity of the 
amino acid sequences and known physiological effects, the TRPC family can be divided 
into four subgroups: TRPC3/6/7, TRPC4/5, TRPC1 and TRPC2. TRPC1 is sometimes 
included in the TRPC4/5 subgroup, and TRPC2 is not expressed in humans[22; 23; 24]. 
While most TRPC subunits can form functional homomeric channels, heteromerization of 
TRPC channel subunits of either the same subfamily or different subfamilies has been 
widely observed to extend functional diversity [25; 26; 27; 28; 29; 30].  
Figure 1.4: Structures of the different TRPs. A, ankyrin repeats; cc, coiled-coil domain; P, pore loop. 
Adapted with permission of Annual Reviews, Inc., from Annual Review of Biochemistry, Vol. 76, 
Venkatachalam K, et al., TRP Channels, Copyright (2007); permission conveyed through Copyright 







1.3    TRPC and kidney 
 
Interestingly, TRPC genes have been implicated in renal fibrosis. TRPC6 is widely 
expressed in renal tissues, including glomerular podocytes, mesangial cells, endothelial 
cells, tubulointerstitial vascular and epithelial cells, as well as in renal blood vessels [31]. 
TRPC6 is one of the podocyte slit-diaphragm proteins associated with proteinuria, which 
is mainly mediated by Ca2+ influx [32]. TRPC6, nephrin, podocin and CD2AP directly or 
indirectly interact with α-actinin-4 to maintain the integrity of the glomerular filtration 
barrier [32; 33]. Podocyte TRPC6 channels play a role in inherited focal segmental 
glomerulosclerosis [21]. Moreover, angiotension II (Ang II), known as an important causal 
driver of chronic kidney disease, can rapidly activate and upregulate the expression of 
TRPC6 in podocytes. Finally, up-regulation of TRPC3 and TRPC6 expression has been 
reported in UUO kidneys [34]. As a result, the intracellular Ca2+ concentration increases 
and eventually leads to podocyte apoptosis and progressive kidney failure [35; 36]. 
 
TRPC3 has been shown to be involved in rat kidney fibroblast proliferation and 
myofibroblast differentiation in vitro [37]. Furthermore, in vivo ablation of Trpc3 in mice or 
pharmacologic inhibition of TRPC3 by the pyrazole compound Pyr3 diminished renal 
fibrosis in the UUO model [37]. To address the potential interplay between TRPC3 and 
TRPC6 in the fibrotic process, Trpc3 and Trpc6 single-knockout mice were compared 
with Trpc3/6 double-knockout mice [34]. Interestingly, knockout of both Trpc3 and Trpc6 
did not diminish UUO-induced fibrosis more than deletion of Trpc6 alone [34]. BTP2, an 
inhibitor of several TRPC channels, including TRPC3 and TRPC6, had an effect similar 
Figure 1.5: Structure of TRPC family members. Reprinted from Cell Calcium, Vol. 38, Pedersen SF, 




to that of a Trpc6 knockout on fibrosis. In addition, BTP2 attenuated the up-regulation of 
Trpc6 expression, which suggests that TRPC6 channel activity may induce its own gene 
expression in the UUO model and play an important role in promoting fibrosis [5]. In line 
with this, genomic deletion of TRPC6 has been observed to inhibit renal fibrosis after 
UUO in mice [34] and rats [38]. The anti-fibrotic effects were explained by a role for 
TRPC3/6 in hetero-tetramers (with or without the contribution of other TRPC channels) in 
interstitial fibroblast activation, differentiation, and proliferation [5]. Alternatively, they may 
be explained by increased homomeric TRPC6 channel activity due to their own increased 
gene expression in the UUO model. However, it is also possible that up- or 
downregulation of other TRPCs, e.g. in myofibroblast or other cell types, could play critical 
roles. For example, diabetic kidneys show reduced TRPC1 expression [39], which 
together with increased TRPC6 activity in podocytes could contribute to glomerulopathy 
[40; 41; 42]. Trcp6-deficiency has also been found to exert some renoprotective benefits 
such as the blunting of an increase in basal calcium in podocytes, reduced foot process 
damage, and a reduction in nephrin shedding in the streptozotocin (STZ)-induced diabetic 
Dahl salt-sensitive (Dahl SS) rat model, a type 1 diabetes mellitus model of diabetic 
nephropathy [43]. Given that the TRPCs have the ability to form homo- and heteromers, 
it is very likely that other TRPC family members additionally contribute to the formation of 
nephropathy in mouse and man. For example, pharmacological inhibition of TRPC5 has 
been found to delay progression of kidney disease due to hypertension [44].  
 
The metabolic syndrome characterized by hypertension, hypoglycemia and lipedema is 
a complex disease leading to kidney disease. The New Zealand Obese (NZO) mouse 
represents one of the most thoroughly investigated polygenic models for the human 
metabolic syndrome and type 2 diabetes. It presents the main characteristics of the 
disease complex, including early-onset obesity, insulin resistance, dyslipidemia, and 
hypertension [45; 46; 47]. To the best of my knowledge, no studies have been reported 









The unilateral ureteral obstruction (UUO) model is a standard and widely used 
experimental model of renal interstitial fibrosis (for review see [48]). Ureteral obstruction 
results in marked renal hemodynamic and metabolic changes, followed by tubular injury 
and cell death by apoptosis or necrosis in conjunction with an infiltration of macrophages 
and other inflammatory cells into the renal interstitium. Proliferation of fibroblasts and 
transformed myofibroblasts are responsible for the excessive production of extracellular 
matrix and accelerated renal fibrosis. Phenotypic transition of resident renal tubular cells, 
endothelial cells, and pericytes has also been implicated in this process [48]. The use of 
genetically engineered mice has greatly expanded the utility of the model for studying 
molecular mechanisms underlying the renal response to UUO.  
 
 
1.5    Hypothesis and aims of the study 
 
The aim of the study here was to understand the therapeutic potential of TRPC6 inhibition 
in renal fibrosis underlying the progression of CKD to end-stage renal disease. The 
hypothesis that up-regulation of renal TRPC6 is a common feature in UUO kidneys 
contributing to renal fibrosis and immune cell infiltration in mice was tested. The UUO 
model was used to induce renal fibrosis and immune cell infiltration, and the expression 
of TRPC channels in the kidneys of wild-type (WT) and Trpc6-knockout (Trpc6-/-) mice 
was analyzed. Furthermore, the therapeutic efficiency of TRPC6 inhibition was evaluated 
in obstructive nephropathy using Trpc6-/- mice. The NZO mouse model[45; 46; 47; 49] 
was used to evaluate UUO nephropathy as well as the regulation of TRPC channel 







Materials and Methods 
 
 
2.1    Animals 
 
Male Trpc6-/- mice (24.51 + 2.73 g body weight (b.w.), n=31, 9-12 weeks old) and age-
matched WT controls (25.69 + 1.79 g b.w., n=32, p>0.05) were used (Figure 2.1A and B). 
The Trpc6-/- mice were generated on C57BL/6J:129/Sv genetic background and 
characterized previously [50]. Since 129Sv and C57BL/6J mice display similar renal 
damage in the UUO model [51], C57BL/6J mice were chosen as control Trpc6+/+ (WT) 
mice. Age-matched male NZO mice (Figure 2.1C) which were obese (39.90 + 4.11 g b.w., 
n=15, p<0.05 versus both WT and Trpc6-/- mice) and carried susceptibility genes (from 
the NZO/BomHIDife genetic background) for obesity, diabetes and hypertension were 
used [45; 46; 47; 49]. All mice were bred and raised in the Max-Rubner-Laboratory (MRL) 
of the German Institute of Human Nutrition (Nuthetal, Germany). The mice were housed 
in groups of three to five and single housing was applied 7 days before and after the UUO 
surgery to ensure uniformity. The mice were reared under specific-pathogen-free (SPF) 
conditions in individually ventilated cages (IVC) with a diurnal 12 h light and dark cycle 
(lights on at 06:00 h) at a temperature of 21±1°C. All animals had free access to water 
and food. The mice were housed and handled according to good animal practice as 
defined by the Federation of European Laboratory Animal Science Associations 
(FELASA)[52] and the national welfare body GV-SOLAS[53]. Animal care followed 
American Physiological Society guidelines [54], and all protocols were locally approved 
(LUGV Brandenburg, Germany; Permit-Number: 2347-7-2016).  
 






2.2    UUO model 
 
All surgical procedures were performed under aseptic conditions. The mice were 
anesthetized with 2% isoflurane and placed on a heating pad to prevent hypothermia. 
After the depth of anesthesia was confirmed by a loss of reflexes (toe pinch), the anterior 
abdominal skin was shaved, wiped with 70% ethanol and 500 mg/kg metamizole (500 
mg/ml, WDT) was injected intraperitoneally (i.p.). Eventually a midline laparotomy was 
conducted via an incision of the avascular linea alba and the left ureter was exposed. The 
ureter was then ligated twice close to the renal pelvis using a 5-0 polyglycolic acid (PGA) 
suture wire (Resorba®), and subsequently, 0.05 ml of a 10% enrofloxacine solution 
(Baytril, Bayer) was applied in the abdominal cavity. Sham operation was performed 
without ureteral ligation. The linea alba and skin were closed separately. The wound was 
sanitized with a silver aluminium spray (Henry Schein®), and 1 ml of warm (37°C) isotonic 
sodium chloride solution (Berlin-Chemie Menarini) was injected subcutaneously (s.c.). 
Subsequently, each mouse was placed in a cage in front of an infrared (IR) lamp and 
monitored until it recovered consciousness. For the following two days mice received 
metamizole (500mg/ml, Lichtenstein) in their drinking water with a final concentration of 
1.33mg/ml. The tissue harvest occurred 7 days after the surgeries (UUO and sham). For 
this, mice were sacrificed with an overdose of isoflurane (1 ml/ml, CP-Pharma) and death 
was confirmed via a lack of reflex formation upon targeted provocation. The left kidneys 
Figure 2.1: Experimental mice. (A) C57BL/6J mice. (B) Trpc6-/- mice. (C) NZO mice. 
Materials and Methods 
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were excised and decapsulated for further analysis. The kidneys were transversely 
divided into two portions. Half of the kidney was immersed in a 4% phosphate-buffered 
paraformaldehyde (PFA) (Sigma) solution for histology, and the other half was snap-
frozen in liquid nitrogen for RNA preparation. 
 
 
2.3    Histology and immunohistochemistry 
 
Paraffin-embedded kidneys were cut in three micrometer thick sections followed by 
deparaffination in sequential steps of xylene, ethanol solutions (100%, 96%, 70%) and a 
final rehydration step in water. For the morphological and histological analyses, Sirius red 
(SR) stains and Periodic acid Schiff (PAS) reactions were performed according to the 
manufacturer’s protocols (Sigma). SR specifically stains collagen type 1 and 3 fibrils and 
allows a quantification of interstitial fibrosis. The PAS reaction allows visualization of the 
basement membranes of the capillary loops of the glomeruli, through which the 
glomerular damage can be evaluated.  
 
For the immunohistochemical (IHC) analysis and the detection of the proteins of interest, 
the following procedure was conducted: antigen retrieval was achieved by immersing the 
samples in boiling sodium citrate buffer (MW-buffer, pH 6.0, S2031, DAKO) in a 
microwave. This included two 4 min steps and one 5 min step at room temperature in 
between. In order to block the endogenous peroxidase activity, the tissues were 
incubated in 3% H2O2 in purified water for 10 min. Furthermore, the tissue was perforated 
using Tris-buffered saline with tween 20 (TBST) buffer for 15 min and potential unspecific 
antibody binding was prevented via a 10 min blocking step with DAKO antibody diluent 
(S3022, DAKO). In between each of these steps, the samples were washed with a TBST 
buffer for 5 min and a final washing step with phosphate-buffered saline (PBS) before the 
incubation with the following primary antibodies: anti-F4/80 (rat monoclonal, 1:8000, 
MCA497GA, Serotec), anti-CD3 (rabbit polyclonal, 1:250, ab5690, Abcam), anti-alpha 
smooth muscle actin (αSMA) (rabbit polyclonal, 1:500, ab5694, Abcam), anti-vimentin 
(rabbit monoclonal, 1:2000, ab92547, Abcam), collagen type 4, alpha 1 (Col4α1) (rabbit 
polyclonal, 1:2000, ab6586, Abcam), anti-proliferating cell nuclear antigen (PCNA) (rabbit 
polyclonal, 1:1000, ab18197, Abcam) and anti-cleaved-caspase 3 (cCasp3) (rabbit 
polyclonal, 1:280, 9661S, Cell Signaling). All primary antibodies were diluted in DAKO 
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antibody diluent and incubated over night at 4°C except for the anti-CD3 antibody, whose 
incubation occurred at room temperature for 1 hour (h). After antibody incubation, the 
samples were washed three times with PBS (5 min each) and Histofine® Simple Stain™ 
MAX PO, which uses the 3,3’-diaminobenzidine (DAB) chromogen, was applied 
according to the manufacturer’s protocol (Nichirei). This allowed the visualization of the 
proteins of relevance. Eventually, the tissue samples were counterstained with 
haematoxylin (Roth) and dehydrated in a sequence of ethanol solutions followed by a 
final xylene dehydration step. The slides were then sealed with mounting medium 
(Histokitt, 1025/500, Hecht) and stored until they were imaged. 
 
 
2.4    Histological analyses 
 
The kidneys of all the animals in each group were analyzed in a blinded manner to 
minimize the observer bias. All slides were scanned by a digital slide scanner 
(PannoramicTM MIDI II, 3DHISTECH) (Figure 2.2). Images were taken with the software 
CaseViewer (3DHISTECH) at either 20x (all IHC stains) or 40x (PAS and SR). The cortex 
of each kidney sample was screened thoroughly starting at one end of the tissue and 
ending at the other. In order to achieve a concise quantification of the area of interest in 
a semiautomatic manner, an NIH ImageJ plug-in, previously generated by Gabriel Landini 
(university of Birmingham), was used. This plug-in allows a color threshold to be set and 
the generation of macros that can be applied individually to all stored images of each 
stain to guarantee consistency. The mesangial expansion and thus glomerular damage 
could be visualized with the PAS stain. For this, the PAS+ area of at least 20 glomeruli in 
each animal was analyzed. This was done by assessing the glomerular perimeter and 
normalizing the positively stained area to the glomerular capillary tuft area. The SR stain 
allowed the quantification of fibrosis in the renal cortex. At least 15 pictures of each SR-
stained kidney were taken and the total positively stained area of each visual field was 
quantified. The F4/80, vimentin, αSMA, Col4α1 positive areas were measured in the 
same manner whereas CD3+ as well as PCNA+ cells were counted individually using the 
ImageJ threshold plug-in as previously mentioned.  
 






2.5    Quantitative real-time (qRT)-PCR 
 
qRT-PCR was performed as described earlier [55]. Briefly, total RNA was isolated from 
the snap-frozen kidney cortex after homogenization with a Precellys 24 homogenizer 
(Peqlab) using the RNeasy RNA isolation kit (Qiagen). RNA quality and concentration 
were determined by a NanoDrop-1000 spectrophotometer (Thermo Fisher Scientific). 
Two micrograms of total renal RNA were transcribed to cDNA (Applied Biosystems). 
Quantitative analysis of target mRNA expression was calculated using the relative 
standard curve method. TaqMan and SYBR green analysis was conducted using an 
Applied Biosystems 7500 Sequence Detector (Applied Biosystems). The expression 
levels were normalized to GAPDH (glyceraldehyde-3-phosphate dehydrogenase) and 
eEF1α1 (eukaryotic translation elongation factor 1 alpha 1), and mean Ct values of each 
groups are reported (Figure 2.3). Primer sequences are provided in Table 2.1. 
 
Gene Forward Reverse 
GAPDH 
5’-TGT GTC CGT CGT GGA TCT GA-
3’ 
5’-CCT GCT TCA CCA CCT TCT TGA-
3’ 
Probe: 5’-6-FAM-TGC CGC CTG GAG AAA CCT GCC-TAMRA -3’ 
Table 2.1: Details of specific primers used in real-time PCR experiments. 
Figure 2.2: PannoramicTM Digital Slide Scanner (PannoramicTM MIDI II). The scanner scans 
automatically up to 12 slides in one run and supports the Carl Zeiss objectives. 




5’-TCG TCG TAA TCG GAC ACG TA-
3’ 
5’-CAG CAG CCT CCT TCT CAA AC-
3’ 
Trpc1 
5’-TGG GCC CAC TGC AGA TTT 
CAA-3’ 
5’-AAG ATG GCC ACG TGC GCT AAG 
GAG-3’ 
Trpc2 
5’-TTG CCT CCC TCA TCT TCC TCA 
CCA-3’ 
5’-CCG CAA GCC CTC GAT CCA CAC 
CT-3’ 
Trpc3 
5’-AGC CGA GCC CCT GGA AAG 
ACA C-3’ 
5’-CCG ATG GCG AGG AAT GGA AGA 
C-3’ 
Trpc4 5’-GGG CGG CGT GCT GCT GAT-3’ 
5’-CCG CGT TGG CTG ACT GTA TTG 
TAG-3’ 
Trpc5 
5’-AAC TCC CTC TAC CTG GCA ACT 
A-3’ 
5’-GGA TAT GAG ACG CAA CGA ACT 
T-3’ 
Trpc6 
5’-GAC CGT TCA TGA AGT TTG TAG 
CAC-3’ 
5’-AGT ATT CTT TGG GGC CTT GAG 
TCC-3’ 
Trpc7(primer1) 5’-GTG GGC GTG CTG GAC CTG-3’ 
5’-AGA CTG TTG CCG TAA GCC TGA 
GAG-3’ 
Trpc7(primer2) 
5’-GCG GCC CCA TGA CTA CTT C-
3’ 
5’-TGG ATA GGG ACA GGT AGG CG-
3’ 
Trpc7(primer3) 
5’-CGT CCA AGT CTG AGC CGA AT-
3’ 
5’-GGT TTG TCC TAG CTT GCT GC-
3’ 
Col1α1 
5’-CAT GTT CAG CTT TGT GGA 
CCT-3’ 
5’-GCA GCT GAC TTC AGG GAT GT-
3’ 
Col3α1 
5’-CTC ACC CTT CTT CAT CCC ACT 
CTT A-3’ 
5’-ACA TGG TTC TGG CTT CCA GAC 
AT-3’ 
Col4α1 
5’-TTA AAG G ACT CCA GGG ACC 
AC-3’ 
5’-CCC ACT GAG CCT GTC ACA C-3’ 
αSMA (ACTA2) 
5’-ACT GGG ACG ACA TGG AAA AG-
3’ 
5’-CAT CTC CAG AGT CCA GCA CA-
3’ 
TGFβ1 
5’-TGG AGC AAC ATG TGG AAC TC-
3’ 
5’-GTC AGC AGC CGG TTA CCA-3’ 
VCAM1 
5’-CTG GGA AGC TGG AAC GAA 
GT-3’ 
5’-GCC AAA CAC TTG ACC GTG AC-
3’ 
ICAM1 
5’-CTG GGC TTG GAG ACT CAG TG-
3’ 
5’-CCA CAC TCT CCG GAA ACG AA-
3’ 
MCP1 (CCL2) 
5’-TTA AAA ACC TGG ATC GGA ACC 
AA-3’ 
5’-GCA TTA GCT TCA GAT TTA CGG 
GT-3’ 
IL1β 
5’-GAA ATG CCA CCT TTT GAC AGT 
G-3’ 
5’-TGG ATG CTC TCA TCA GGA CAG-
3’ 
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IL6 5’-ATC CTC TGG AAC CCC ACA C-3’ 
5’-GAA CTT TCG TAC TGA TCC TCG 
TG-3’ 
TNFα 
5’-CTG AAC TTC GGG GTG ATC GG-
3’ 







2.6    Statistical analyses 
 
Statistical analyses were performed using GraphPad Prism 7.0 (GraphPad Software). All 
data are presented as mean ± SD and p-values of <0.05 were considered as statistically 
significant. The p-values in the figures are denoted as follows: ns p>0.05, *p<0.05, 
**p<0.01, ***p<0.001 and ****p<0.0001. Data were analyzed by regular two-way ANOVA 
with Bonferroni’s multiple comparisons test. Data with two groups were tested by two-
sided unpaired t-test (data with normal distribution). 
 
 
Figure 2.3: Average CT values of two housekeeping genes: Glyceraldehyde-3-Phosphate 
Dehydrogenase (GAPDH) and Eukaryotic Translation Elongation Factor 1 alpha 1 (eEF1α1). There is 
no statistical significance between sham-operated groups and UUO-operated groups in wild-type (WT), 







3.1    UUO induces renal damage and apoptosis 
 
Urinary tract obstruction led to hydronephrosis, caused by urine stasis in the renal pelvis 
or calyces, in all UUO kidneys (Figure 3.1). The glomerular and tubular basement 
membrane as well as the brush border of the proximal tubules were visualized by periodic 
acid Schiff (PAS) staining. The increases in mesangial matrix deposition in the glomeruli 
in both WT UUO and Trpc6-/- UUO versus sham kidneys implicates renal damage induced 
by UUO (Figure 3.2A and B). Moreover, there were no differences in glomerular injury in 
WT versus Trpc6-/- kidneys upon UUO, indicating similar glomerular damage in both 




Figure 3.1: Macroscopic analysis of the kidneys. Images of the left (L) and right (R) kidneys of (A) 
Wild type (WT) mice, (B) Trpc6-/- mice and (C) NZO mice. The left UUO kidneys of all mice increased 







Next, sections of the kidneys were stained with antibodies against proliferating cell 
nuclear antigen (PCNA, to determine the mean proliferation index of PCNA) (Figure 3.3A) 
and programmed cell death marker cleaved-caspase 3 (cCasp3) (Figure 3.3C). UUO-
induced increases in PCNA positive (PCNA+) cells and cCasp3 positive (cCasp3+) cells 
were clearly visible in the kidneys of both WT and Trpc6-/- mice. Although there was no 
difference in the number of PCNA+ cells between UUO WT and Trpc6-/- kidneys (Figure 
3.3B), fewer cCasp3 positive cells were found in Trpc6-/- UUO kidneys compared to WT 
UUO kidneys, indicating that ureteral obstructed Trpc6-/- kidneys show less apoptosis 
compared to obstructed WT kidneys (Figure 3.3D). 
 
Figure 3.2: PAS stained kidneys. (A): Kidneys stained with the periodic acid Schiff (PAS) stain to 
detect glomerular damage. (B) Quantification of the PAS positive areas in the kidneys. All images were 
taken at a magnification of 40x. Scale bar: 50 μm. All values are means ± SD. ns p>0.05, ***p<0.001 
and ****p<0.0001. Wild type (WT) and Trpc6-/- sham groups included n=5 kidney samples each. WT 








3.2    Role of TRPC6-deficiency in renal inflammation 
 
UUO induces immune responses such as infiltration of blood cells leading to renal 
inflammation [48]). Therefore, it was determined whether Trpc6-deletion can affect renal 
immune infiltration as well as mRNA expression of pro-inflammatory markers in the 
kidneys. Antibodies against the macrophage marker F4/80 and the T-cell marker CD3 
were applied in IHC analyses. UUO caused immune cell infiltration in WT and Trpc6-/- 
kidneys, as assessed by F4/80 positive (F4/80+) areas and the numbers of CD3 positive 
(CD3+) cells in the respective kidney sections (Figure 3.4A-D). However, this infiltration 
Figure 3.3: Markers of proliferation and apoptosis. (A) Proliferating cell nuclear antigen (PCNA) 
antibody staining: marker of cell regeneration. (B) Quantification of renal cells positively stained for 
PCNA. (C) Cleaved-caspase 3 (cCasp3) antibody staining: marker of apoptosis. (Arrows: cCasp3+ 
cells) (D) Quantification of renal cells positively stained for cCasp3. All images were taken at a 
magnification of 20x. Scale bar: 100 μm. All values are means ± SD. ns p>0.05, ***p<0.001 and 
****p<0.0001. Wild type (WT) and Trpc6-/- sham groups included n=5 kidney samples each. WT and 





was smaller in Trcp6-/- UUO kidneys compared to WT UUO kidneys (Figure 3.4A-D), 





Next, qRT-PCR was applied to analyse mRNA expression of the pro-inflammatory 
markers interleukin 1 beta (IL1β), interleukin 6 (IL6), tumor necrosis factor alpha (TNFα), 
intercellular adhesion molecule 1 (ICAM1), vascular cell adhesion molecule 1 (VCAM1), 
and monocyte chemotactic protein 1 (MCP1). As a result, all mentioned markers were 
found to be significantly increased upon UUO in the renal cortex of both WT and Trpc6-/- 
Figure 3.4: Markers of inflammation in wild-type (WT) and Trpc6-/- kidneys. (A) F4/80 antibody 
staining: macrophage marker. (B) Quantification of the F4/80 positive areas. (C) CD3 antibody staining: 
T-cell marker. (D) Quantification of the CD3 positive cells. WT and Trpc6-/- l UUO-treated groups 
encompassed n=12 (WT) and n=11 (Trpc6-/-) kidney samples. All quantification data are means ± SD. 
ns p>0.05, *p<0.05, **p<0.01 ***p<0.001 and ****p<0.0001. WT and Trpc6-/- sham groups included n=5 





kidneys (Figure 3.5). There were no differences observed between mRNA expression of 
IL1β, IL6 and TNFα in Trpc6-/- UUO and WT UUO kidneys (Figure 3.5A-C). However, it 
was found that Trpc6-/- UUO kidneys displayed increased mRNA expression levels of 
ICAM1, VCAM1 and MCP1 relative to WT UUO kidneys (Figure 3.5D-F). 
 
 
Figure 3.5: Expression of inflammatory markers in wild-type (WT) and Trpc6-/- kidneys. Renal 
mRNA levels of (A) interleukin 1 beta (IL1β), (B) interleukin 6 (IL6), (C) tumor necrosis factor alpha 
(TNFα), (D) intercellular adhesion molecule 1 (ICAM1), (E) vascular cell adhesion molecule 1 (VCAM1) 
and (F) monocyte chemotactic protein 1 (MCP1) in sham-operated groups and in UUO-operated 
groups. Renal mRNA expression data were determined in n=5 each for sham-operated WT and Trpc6-
/- kidneys, n=9 for UUO-operated WT kidneys and n=8 for UUO-operated Trpc6-/- kidneys. The relative 
standard curve method was used for relative quantification. All data are means ± SD, ns p>0.05, 






3.3    Role of TRPC6-deficiency in renal fibrosis 
 
To examine a possible role of TRPC6-deficiency in renal fibrosis, histological analysis 
including IHC and gene expression measured by qRT-PCR were performed. A Sirius red 
(SR) stain was performed and SR positive (SR+) areas were quantified (Figure 3.6A, B) 
to assess the degree of collagen deposition in the kidneys. Sham-treated kidneys of either 
genotype exhibited only small areas of SR+ areas (Figure 3.6A). In contrast, WT UUO 
kidneys displayed a 6fold increase in SR+ areas compared to controls. This increase in 
collagen deposition was smaller in Trpc6-/- UUO kidneys compared to WT UUO kidneys 
(Figure 3.6B). Next, IHC studies were performed using antibodies against collagen type 
4 alpha 1 (Col4α1) to determine the level of fibrosis, the mesenchymal marker vimentin 
to identify epithelial-to-mesenchymal transition (EMT) of tubular epithelial cells, and alpha 
smooth muscle actin (αSMA) to detect myofibroblasts and mesangial cells as indicators 
of cell types involved in fibrosis (Figure 3.6C-H). As a result, a significant increase was 
observed in the Col4α1 positive (Col4α1+) area in UUO kidneys compared to sham 
kidneys of both genotypes (Figure 3.6C, D). However, this increase in the Col4α1 positive 
(Col4α1+) area was smaller in Trpc6-/- UUO kidneys compared to WT UUO kidneys 
(Figure 3.6C, D). Furthermore, a marked increase in the vimentin positive (vimentin+) area 
(Figure 3.6E, F) and the αSMA positive (αSMA+) area (Figure 3.6G, H) was observed in 
UUO kidneys of both genotypes. Again, the increase in vimentin+ mesenchymal cells and 
αSMA+ myofibroblasts was smaller in Trpc6-/- UUO kidneys compared to WT UUO 
kidneys (Figure 3.6E-H). Taken together, these data suggest a protective effect in renal 






Figure 3.6: Expression of fibrosis markers. (A) Sirius red (SR) staining (40x, Scale bar: 50 μm). (B) 
Quantification of the SR positive areas. (C) Collagen type 4, alpha 1 (Col4α1) antibody staining: fibrosis 
marker (20x, Scale bar: 100 μm). (D) Quantification of the Col4α1 positive areas. (E) Vimentin antibody 
staining: mesenchymal marker (20x, Scale bar: 100 μm). (F) Quantification of the vimentin positive 
areas. (G) Alpha smooth muscle actin (αSMA) antibody staining: myofibroblast marker (20x, Scale bar: 
100 μm). (H) Quantification of the αSMA positive areas. Wild type (WT) and Trpc6-/- sham groups 
included n=5 kidney samples each. WT and Trpc6-/- UUO-treated groups encompassed n=12 (WT) and 
n=11 (Trpc6-/-) kidney samples. All quantification data are means ± SD. ns p>0.05, *p<0.05, ***p<0.001 




Using qRT-PCR, the mRNA expression of pro-fibrotic markers in the renal cortex was 
analysed, including collagen type 1 alpha 1 (Col1α1), collagen type 3 alpha 1 (Col3α1), 
collagen type 4 alpha 1 (Col4α1), transforming growth factor beta 1 (TGFβ1) and αSMA 
(Figure 3.7). Whereas UUO caused increased mRNA expression of all pro-fibrotic 
Figure 3.7: Expression of genes involved in renal fibrosis in kidneys of wild-type (WT) and Trpc6-/- 
mice. Renal mRNA levels of (A) collagen type 1, alpha1 (Col1α1), (B) collagen type 3, alpha1 (Col3α1), 
(C) collagen type 4, alpha1 (Col4α1), (D) transforming growth factor beta 1 (TGFβ1) and (E) alpha smooth 
muscle actin (αSMA) in sham-operated groups and in UUO-operated groups. Renal mRNA expression 
data were determined in n=5 each for sham-operated WT and Trpc6-/- mice, n=9 for UUO-operated WT 
mice and n=8 for UUO-operated Trpc6-/- mice. The relative standard curve method was used for relative 





markers in the renal cortex of WT mice (Figure 3.7A-E), Trpc6-deficiency UUO kidneys 
displayed only a significant increase in Col3α1, Col4α1 and TGFβ1 but not αSMA mRNA 
levels (Figure 3.7B, C, D). Comparing the mRNA expression of the aforementioned 
markers within the UUO-treated groups, all pro-fibrotic markers except TGFβ1 were found 
to be reduced in Trcp6-/- UUO kidneys relative to WT UUO kidneys (Figure 3.7A-E) 
supporting the idea that Trpc6-deficiency is protective in this kidney disease model.  
 
 
3.4    Expression profile of TRPC channels in the renal cortex 
 
The genomic absence of one TRPC channel may affect the expression of the remaining 
ones, which could contribute to the renal outcome. qRT-PCR was performed to first 
identify the relative expression of TRPC family members (TRPC1-7) in the renal cortices 
of WT and Trpc6-deficient mice. In sham-operated kidneys, deletion of Trpc6 was found 
to be associated with reduced Trpc2, Trpc3 and Trpc4 mRNA expression compared to 
WT kidneys (Figure 3.8A-D). Conversely, Trpc6-deficiency increased Trpc1 mRNA 
expression. Similarly, Trpc5 mRNA was present in Trpc6-/- kidneys but below the 
detection limit in WT kidneys (Figure 3.8E, Figure 3.9A). As reported earlier [34], whereas 
Trpc6 mRNA expression could be determined in WT kidneys, it was below the detection 
levels in Trpc6-/- kidneys(Figure 3.8F).Trpc7 mRNA was not detectable in both WT and 
Trpc6-/- kidneys, but was present in WT brain tissue, which served as a positive control 
(Figure 3.9B).  
 
Next, it was determined whether in WT animals the relative expression of TRPC isoforms 
is affected by UUO. Interestingly, ureter obstruction did not affect the relative mRNA 
expression levels of most TRPC family members including Trpc2, Trpc3, Trpc4, and 
Trpc5 (Figure 3.8B,C,D,E). In contrast, UUO provoked an approximately 50% 
downregulation of Trpc1 and notably a 60% upregulation of Trpc6 mRNA expression in 
WT kidneys (Figure 3.8A and F) relative to sham-operated WT animals.  
 
Finally, the impact of Trpc6-deficiency on the relative TRPC-isoform expression profile in 
UUO kidneys was studied. Under these conditions, a highly significant decrease of Trpc2 
and Trpc4 transcript levels was evident in the knockout kidneys (Figure 3.8B,D) whereas 




addition, Trpc5 transcript levels were below detection levels in the presence and absence 





Figure 3.8: Expression of renal TRPC channels in wild-type (WT) and Trpc6-/- mice.  Renal mRNA 
levels of (A) transient receptor potential cation channel 1 (TRPC1), (B) TRPC2, (C) TRPC3, (D) TRPC4, 
(E) TRPC5 and (F) TRPC6 in sham-operated groups and in UUO-operated groups. Renal mRNA 
expression data were determined in n=5 each for sham-operated WT and Trpc6-/- mice, n=9 for UUO-
operated WT mice and n=8 for UUO-operated Trpc6-/- mice. The relative standard curve method was 
used for relative quantification. All data are means ± SD., ns p>0.05, **p<0.01, ***p<0.001, 








3.5    UUO in NZO mice  
 
Next, the complex disease NZO mouse model was used to evaluate UUO nephropathy 
and regulation of TRPC channel expression in an inbred obese mouse strain carrying 
susceptibility genes for diabetes and hypertension. In the NZO mice, UUO also caused 
significant damage to the kidney. Histological analyses showed that UUO induced 
increases in the PAS+ area, PCNA+ cells, SR+ area, F4/80+ area and CD3+ cells (Figure 
3.10). Furthermore, a UUO-induced increase was detected in mRNA expression of the 
pro-fibrotic markers Col1α1, Col3α1, Col4α1 and TGFβ1 (except αSMA) (Figure 3.11A) 
and the pro-inflammatory markers IL1β, IL6, TNFα, ICAM1, VCAM1 and MCP1 relative 
to the sham-operated group (Figure 3.11B).  
 
Figure 3.9: Expression of Trpc5 and Trpc7 mRNA in brain and kidney samples in wildtype (WT) 
mice. (A) Trpc5 mRNA expression and (B) Trpc7 mRNA expression (detected by three primer pairs 
with different sequences). At mRNA level, Trpc5 and Trpc7 are highly expressed in brain but not in 







Figure 3.10: Markers of fibrosis and inflammation in New Zealand obese (NZO) mice. (A) Periodic 
acid Schiff (PAS) stain: marker of glomerular damage (40x. Scale bar: 50 μm). Proliferating cell nuclear 
antigen (PCNA) antibody stain: marker of cell regeneration (20x. Scale bar: 100 μm). Sirius red (SR) 
stain: marker of interstitial fibrosis (40x. Scale bar: 50 μm). F4/80 antibody stain: macrophage marker 
(20x. Scale bar: 100 μm) and CD3 antibody stain: T-cell marker (20x. Scale bar: 100 μm) in sham-
operated group and UUO-operated groups. (B) All quantification data are means ± SD. Data were 
determined in n=5 for sham-operated kidneys, n=10 for UUO-operated kidneys. **p<0.01, ***p<0.001 






Figure 3.11: Expression of markers of fibrosis and inflammation in New Zealand obese (NZO) 
mice. (A) Renal mRNA levels of fibrosis markers: collagen type 1, alpha 1 (Col1α1), collagen type 3, 
alpha 1 (Col3α1), collagen type 4, alpha 1 (Col4α1), transforming growth factor beta 1 (TGFβ1) and 
alpha smooth muscle actin (αSMA) in sham-operated group and in UUO-operated group. (B) Renal 
mRNA levels of inflammation markers: interleukin 1 beta (IL1β), interleukin 6 (IL6), tumor necrosis factor 
alpha (TNFα), intercellular adhesion molecule 1 (ICAM1), vascular cell adhesion molecule 1 (VCAM1) 
and monocyte chemotactic protein 1 (MCP1) in sham-operated group and UUO-operated groups. All 
mRNA expression data were determined in n=5 for sham-operated kidneys, n=9 for UUO-operated 
kidneys. The relative standard curve method was used for relative quantification. All data are means ± 





The relative expression profile of TRPC genes was also examined in kidneys of NZO 
mice in sham and UUO kidneys by qRT-PCR. NZO sham kidneys expressed mRNA of 
six TRPC genes in the renal cortex (Figure 3.12). UUO caused up-regulation of Trpc6 
mRNA expression while Trpc1 and Trpc5 mRNA expression was down-regulated. There 
was no change in Trpc2 and Trpc3 mRNA expression in NZO kidneys upon UUO surgery 
(Figure 3.12). It is noteworthy that Trpc7 mRNA was not detectable in NZO kidneys 
without UUO or in response to UUO (Figure 3.12), which is in line with the findings in WT 










Figure 3.12: Expression of renal TRPC channels in New Zealand obese (NZO) mice.  Renal mRNA 
levels of TRPC1-7 channels in sham-operated group and in UUO-operated group. Renal mRNA 
expression data were determined in n=5 for sham-operated kidneys, n=9 for UUO-operated kidneys. 
The relative standard curve method was used for relative quantification. All data are means ± SD, 







The major findings of the study are threefold. First, the findings provide evidence for a 
marked up-regulation of renal TRPC6 expression upon UUO in WT and NZO mice. This 
up-regulation is associated with renal fibrosis and immune cell infiltration in both mouse 
models. A striking reduction of fibrosis was observed after genomic deletion of TRPC6, 
which was associated with reduced immune cell infiltration. On a conceptual level, these 
findings are consistent with the idea that TRPC6 fulfills an important role in promoting 
renal fibrosis after UUO in mice. Second, the study further reveals an unrecognized down-
regulation of Trpc2 and Trpc4 mRNA expression in Trpc6-/- sham and Trpc6-/- UUO 
kidneys compared to WT sham and WT UUO kidneys, respectively, which suggests that 
TRPC2/4 could also fulfill inhibitory functions in renal fibrosis, at least after genomic 
deletion of TRPC6. Third, a significant down-regulation of Trpc1 and Trpc5 mRNA levels 
was observed in UUO kidneys of NZO mice, which indicates that these genes could play 
an additional protective role in renal fibrosis and inflammation in a polygenic environment 
with susceptibility genes for obesity, diabetes and hypertension. Although most TRPC 
subunits can form functional homomeric channels, heteromerization of TRPC channel 
subunits of either the same subfamily or different subfamilies has been widely observed 




4.1    TRPC6 in the kidney 
 
The structural and functional defects of the glomerular filtration barrier are central 
mechanisms of proteinuric kidney disease. TRPC6, which is regarded as a key molecule 
of the slit-diaphragm, can be increasingly detected in various kidney diseases such as 
FSGS [56; 57], diabetic nephropathy [42; 58; 59; 60], minimal change nephrosis [57; 61] 
and membranous nephropathy [61; 62; 63]. Recent studies show that genomic inhibition 
of TRPC6 can reduce rat kidney fibroblast proliferation and myofibroblast differentiation 
in vitro and thereby diminishes renal fibrosis in the UUO model [34; 38]. In the present 




mouse strains were used: WT, Trpc6-/- and NZO mice. By performing such experiments, 
an effort was made to evaluate the therapeutic efficiency of genomic TRPC6 inhibition in 
obstructive nephropathy in the UUO model and to determine the effect of TRPC6 ablation 
and UUO on the expression of all seven TRPC channels in the kidneys of the three 
different genotypes. In line with previous findings, the data show that genomic deletion of 
TRPC6 is associated with a reduction of renal fibrosis in the UUO mouse model. In 
addition, TRPC6-deletion is also associated with less inflammatory cell infiltration in UUO 
kidneys. It is further revealed that TRPC6-deficiency per se impacts on renal TRPC 
channel expression in mice as indicated by reduced mRNA expression of TRPC2, TRPC3 
and TRPC4 and increased mRNA expression of TRPC1. Moreover, UUO is found to 
cause reduced Trpc1 mRNA and increased Trpc6 mRNA expression without changes of 
Trpc3 expression in WT kidneys and also in the kidneys of NZO mice. Collectively, the 
data suggest that counterbalanced or increased expression of TRPC1 and TRPC6 could 
play a role in UUO-induced kidney damage. Since genomic deletion of Trpc6 improved 
renal fibrosis and was associated with an increase of Trpc1 mRNA expression and a 
reduction of Trpc2 and Trpc4 mRNA expression to levels similar or even greater than 
those observed in WT UUO/sham-operated kidneys, it can be concluded that TRPC6 
could drive renal fibrosis with or without modifying effects of TRPC1/2/4.  
 
 
4.2    TRPC6 and TRPC3 
 
Of note, the data in the present study show that the deficiency of TRPC6 is associated 
with reduced Trpc3 mRNA expression in Trpc6-/- kidneys compared to WT kidneys, which 
disappears in obstructive nephropathy. At first glance, this is surprising as it was observed 
in a previous publication on Trpc6-/- mice that loss of TRPC6 is associated with up-
regulation of constitutively active TRPC3-type channels in some arteries [50]. However, 
according to present knowledge, TRPC channel (TRPC1-7) expression and resulting 
putative (functional) counterbalancing effects have not been investigated in experimental 
obstructive nephropathy. This is of particular interest for TRPC3, which is capable of 
contributing to fibrogenesis and tissue inflammation [37; 64; 65; 66; 67]. Additionally, Wu 
et al. reported that TRPC3 mRNA expression is upregulated in UUO-induced renal 
fibrosis in both WT and Trpc6-/- mice[34]. However, the present data do not show an 




is an argument against it playing an important role in the progression of fibrosis in 
obstructive nephropathy. Based on the findings, it is unlikely that increased TRPC3 
expression upon UUO accounts for the beneficial role of TRPC6-deficiency in this model 
of kidney failure. These mechanisms might be particularly relevant for inherited FSGS 
caused by mutations in TRPC6 [21; 68]. This conclusion is supported by the findings 
demonstrating that knockout of both TRPC3 and TRPC6 did not diminish UUO-induced 
fibrosis more than deletion of TRPC6 alone [34]. BTP2, an inhibitor of several TRPC 
channels, including TRPC3 and TRPC6, had an effect similar to that of Trpc6 knockout 
on fibrosis, but also attenuated the up-regulation of TRPC6 expression, which suggests 
that TRPC6 channel activity may induce its own gene expression in the UUO model [5] 
and promote fibrosis in this model. Nevertheless, future studies using more specific 
TRPC3/6 blockers are necessary to clarify the contribution of TRPC3 in the absence and 
presence of functional TRPC6 channels. Recently, novel TRPC6 blockers have been 
developed [69; 70; 71], and these could represent important tools for evaluating the role 
of TRPC6 under these conditions.  
 
 
4.3    TRPC6 and TRPC5 
 
Whether TRPC5 activity mediates FSGS onset and progression is unknown. Recently, 
Zhou et al. identified a small molecule, AC1903, which specifically blocks TRPC5 channel 
activity in glomeruli of proteinuric rats [44]. Chronic administration of AC1903 suppressed 
severe proteinuria and prevented podocyte loss in a transgenic rat model of FSGS. 
AC1903 also provided therapeutic benefit in a rat model of hypertensive proteinuric 
kidney disease [44]. Their data indicate that TRPC5 activity drives kidney disease and 
that TRPC5 inhibitors may be valuable for the treatment of progressive proteinuric kidney 
diseases. The present study reveals a previously unrecognized renal counter-regulation 
of TRPC5 and TRPC7 gene expression, which paralleled the increased expression of 
TRPC6 at mRNA levels in UUO kidneys of NZO mice. It is possible that this counter-
regulation represents an intrinsic mechanism to delay TRPC6-driven renal fibrosis and 
inflammation in a genetic context/background (NZO/HIBomDife) carrying susceptibility 
genes for obesity, diabetes and hypertension. This conclusion is supported by findings 
that TRPC5 is not expressed in normal kidneys of mice [72], but in kidneys of rats [44; 73; 




applied to examine detailed TPRC5 expression. Future studies should also evaluate the 
potential of specific drug targeting of TRPC5 under these conditions. Based on the 
expression data, it is expected that specific TRPC5 inhibition is of little value for limiting 
progressive kidney disease in Trpc6-deficiency, which might have important implications 
for treatment options in human FSGS caused by loss-of-function TRPC6 mutations [68]. 
Nevertheless, future studies are necessary to test and clarify the role of pharmacological 
TRPC5 targeting by agonists and antagonists under these conditions.    
 
While most TRPC isoforms can form functional homomeric or heteromeric TRPC 
channels, and even include TRP isoforms from different subfamilies, the above 
documented up- or down-regulation of the individual TRPC channels may cause 
functional diversity of the various TRPCs in the process of fibrosis and inflammation in 
UUO kidneys. Additional diversification might be caused by the various cell types with the 
individual TRPC channel subunits, which extend functional diversity and are assumed to 
affect the outcome. Therefore, there is an urgent need to test the potency of specific 
pharmacological TRPC modulators, e.g. TRPC6 blockers and TRPC1 agonists, to reveal 
the contribution of the individual TRPC channel subfamilies to the progression of chronic 
kidney disease.  
 
 
4.4    Renal fibrosis and inflammation 
 
Mechanisms that promote kidney disease progression include renal atrophy, fibrosis and 
increased leukocyte infiltration into the kidneys [75; 76]. Renal fibrosis and inflammation 
are two histological hallmarks of progressive kidney disease and specific antibody 
staining is a common tool for estimating renal damage [77; 78]. It is tempting to speculate 
that a similar process is involved in UUO, which contributes to fibrosis and chronic kidney 
failure [48].In previous studies, TRPC6 was reported to contribute to fibroblast-to-
myofibroblast transdifferentiation (FMT) and is thought to promote tissue scarring [79; 80; 
81]. Recent research shows that TRPC6 is involved in the pathogenesis of kidney fibrosis 
and that genomic inhibition of TRPC6 can ameliorate renal fibrosis [34; 38]. TRPC6 is a 
member of non-selective cation channels, indicating that increased Ca2+ flux could be 
one of the pathogenetic factors in myo-/fibroblasts [82]. This study found that Trpc6 loss 




TRPC6-deficiency caused a decreased mRNA expression of multiple pro-fibrotic genes. 
These results therefore confirm the previous finding that Trpc6 deletion attenuates UUO-
induced kidney fibrosis in mice [34]. 
 
The renal damage occurring in CKD is, at least in part, promoted by the immune system 
[83]. Most kidney diseases involve an accumulation of immune cells of the innate immune 
system (e.g. macrophages and neutrophils) and of the adaptive immune system (e.g. T 
cells). In particular, tubulointerstitial monocyte immune infiltration can mediate tissue 
remodeling that ultimately promotes fibrogenesis, renal atrophy and thus kidney failure 
[84; 85; 86]. Until now, no putative immunoregulatory role of TRPC6 has been reported 
in obstructive nephropathy. In the present study, the results of histological analyses show 
a reduction of the inflammatory cell infiltration in Trpc6-/- kidneys compared with WT 
kidneys after UUO. It is noteworthy that UUO provoked an increase in mRNA expression 
of the pro-inflammatory markers in both Trpc6-/- and WT kidneys. However, a significant 
beneficial effect of the Trpc6-knockout was not found on the expression of pro-
inflammatory markers at the mRNA level upon UUO surgery. Taken together, these data 
point to a complex (in-)direct contribution of TRPC6 to renal inflammation in the UUO 
model.  
 
To estimate renal apoptosis as well as regenerative potential, kidney sections were 
stained with antibodies against the apoptosis marker cleaved-caspase 3 (cCasp3) and 
the mitosis marker proliferating cell nuclear antigen (PCNA). Since cCasp3 and PCNA 
levels correlate positively with renal injury, they are commonly used to determine the 
degree of renal damage under chronic damaging conditions [87; 88; 89]. It is known that 
chronic activation of TRPC6 is positively correlated with the rate of apoptosis in cells such 
as podocytes [90; 91] and endothelial cells [92]. In this study, a reduction of cCasp3+ cells 
is observed in Trpc6-/- UUO kidneys. It might also reflect less inflammatory cell infiltration 
in the kidneys of Trpc6-/- mice. PCNA is known as a probe for the detection of cell 
proliferative activity[93]. PCNA+ cells in the present study were found to be increased 
after UUO in both WT and Trpc6-/- kidneys. Nevertheless, there was no significant 
difference in PCNA+ cells between WT and Trpc6-/- mice. Correlated with the result of 
cCasp3 cell infiltration, it might be due to an imbalance between cell apoptosis and 




p53[94] and DNA damage binding protein 2 (DDB2)[95]. In short, the results indicate that 
TRPC6-deficiency protects renal cells from UUO-induced apoptosis. 
 
 
4.5    Diabetic nephropathy 
 
Nowadays, 25-40% of diabetic patients suffer from diabetic nephropathy [96; 97]. Thus, 
diabetic patients can be considered high-risk patients for the development of chronic 
kidney disease. Diabetic nephropathy shows pronounced glomerular changes that are 
present in patients with long-standing diabetes often even before the detection of albumin 
in the urine. Several mechanisms that can lead to diabetic nephropathy are under 
discussion. It has been evaluated whether a UUO-operated NZO mouse model could 
represent a model of progressive nephropathy in co-morbid conditions of obesity, 
hypertension and type 2 diabetes [46], which had not been reported before. Present 
results show that UUO can successfully induce renal fibrosis and inflammatory infiltration 
in the NZO mouse model (NZO/HIBomDife) carrying susceptibility genes for obesity, 
diabetes and hypertension. This study also suggests that changed expression of TRPC 
channels, specifically TRPC1, TRPC5 and TRPC6, could be involved in this process. The 
results suggest that the UUO-operated NZO mouse model might be a valuable mouse 
model for use in evaluating the specific contribution of TRPC6 and other TRPC channel 
subfamilies to renal injury in individuals with obesity, hypertension and diabetes. This 
approach could benefit from better testing, i.e. TRPC subfamily specific blockers and 
agonists. Due to recent progress in this field [44; 69; 70; 71], it is to be hoped that such 






Conclusions and Future Directions 
 
 
In this study, it was observed for the first time that inhibition of TRPC6 is associated with 
a decrease in inflammatory cell infiltration in the murine UUO model. Also, the findings of 
this study are in line with the concept that up-regulation of TRPC6 contributes to fibrosis 
in UUO kidneys, which supports the view that increased TRPC6 expression can play an 
important pathophysiological role in the development of progressive kidney disease [32; 
57; 98; 99]. Moreover, the present results imply that the genomic loss of TRPC6 is 
associated with dysregulation of multiple TRPC channels (TRPC1-4) under chronic 
kidney damaging conditions, which could represent additional drivers of renal fibrosis and 
chronic kidney disease. The results show that UUO also causes up-regulation of TRPC6 
in kidneys of NZO mice, which implies that inhibition of TRPC6 is also a promising 
therapeutic strategy for the treatment of renal fibrosis and immune cell infiltration in 
polygenic models for human metabolic syndrome and type 2 diabetes. 
 
Further studies are required to demonstrate the complex role of TRPC6 in the progression 
of renal insufficiency, from AKI to CKD and ESRD. Meanwhile, studies are needed to 
confirm whether TRPC6 has the same effects on renal insufficiency based on different 
causes, e.g. diabetic nephropathy, hypertensive nephropathy and glomerulonephritis. 
Thus, more kidney models and animal strains could be taken into consideration. It might 
also be interesting to see whether the effects of TRPC6-specific blockers may differ from 
those of global inhibition of TRPC6 by gene knockout. With regard to future drug 
treatment of kidney diseases, the further studies would be the important theoretical basis 
for the discovery of drugs with tolerable TRPC6-specific blockers, i.e. TRPC6-blocking 
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